Analysis of Cycle-by-Cycle and Total Lesional Absorbed Dose (AD) vs. Change in Tumor Size 6 Months Post-therapy in GEP-NET Patients Treated with 177 Lu-DOTATATE: Importance of High AD in Early Cycles (EANM 2026) - Sep 29, 2026 - Abstract #OP-679; Pres time: Oct 20, 2026; 03:00 PM - 04:30 PM; Location: Hall B; P1/2 | "Materials and As part of NCT04086485, a prospective trial evaluating the combination of 177Lu-DOTATATE and olaparib in gastroenteropancreatic neuroendocrine tumors (GEP-NET), 12 patients had three quantitative SPECT/CTs performed at 4, 24, and 48 hours after each cycle of 177Lu-DOTATATE (7.4 GBq every 8 weeks for 4 cycles). AD delivered to a tumor during cycles 1 and 2 of 177Lu-DOTATATE correlated much more strongly with its change in size 6 months after completion of therapy vs. AD delivered during cycles 3 and 4. This suggests potential advantage in front-loading AD in multi-cycle treatments."
Clinical • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor
|
|
F. Lin 1; J. del Rivero 1; J. Zou 1; I. Shamis 1; L. Lindenberg 1; E. Mena-Gonzalez 1; I. B. Turkbey 1; T. Magee 1; Y. Teng 2; C. Millo 3; P. Herscovitch 3; R. Maass-Moreno 3; S. Adler 1; P. Choyke 1; J. Carrasquillo 1, 4
|